KRAS and neoplasm: Recently, two inhibitors (Sotorasib and Adagrasib) were approved by the US Food and Drug Administration (FDA) for the treatment of previously-treated patients with KRAS G12C-mutated NSCLC and are under clinical testing for many other KRAS G12C-mutated tumor types [21].